HERNEXEOS® (zongertinib) and JASCAYD® (nerandomilast) launched in H2, 2025 Group net sales increased 7.3%* to EUR 27.8 billion in 2025 R&...
SK pharmteco, a leading global contract development and manufacturing organization (CDMO), and Prozomix, a pioneer in enzyme discovery and diversity,...
Wilmington PharmaTech (“Wilmington”), a leading U.S.-based research, development, and manufacturing organization (CRDMO) focused on complex c...
Gilead Sciences, Inc. (Nasdaq: GILD) announced it has entered into a definitive agreement to acquire Ouro Medicines, a privately held biotechnology...
New “Danaher Beacon,” first in the European Union, aims to accelerate translation, scalability, and reliability across cell and gene therap...
Imaginostics, Inc. announced that it has received a Letter of Support from Siemens Healthineers in connection with ongoing exploratory discussions ...
In the U.S., FDA approval establishes Opdivo in combination with doxorubicin, vinblastine and dacarbazine (AVD) as the first immunotherapy combination ...
Curi Bio, a world leader in human-relevant 3D tissue technology, and Battelle, the world’s largest independent nonprofit research and development o...
Study conducted in collaboration with the Neuroregeneration Institute at McLean Hospital Autologous neuronal cell therapy for Parkinson’s diseas...
For the primary endpoint, retatrutide lowered A1C by an average of 1.7% to 2.0% across doses at 40 weeks in TRANSCEND-T2D-1 Participants taking retatrut...
Congruence Therapeutics announced that the first participant has been dosed in its Phase 1/1b clinical trial evaluating CGX-926, an oral small-mole...
Curia, a leading contract research, development and manufacturing organization (CDMO), announced progress on the expansion at its Glasgow, UK sterile dru...
Primary endpoint met in Phase 3 TALAPRO-3 study demonstrating a statistically significant and clinically meaningful reduction in risk of disease prog...
— $9M Second Phase of CDMO Investment Builds on 2025 $6M Expansion, Funding Facility Upgrades and Increased Capacity for Suppository, Semi-Solid,...
© 2026 Biopharma Boardroom. All Rights Reserved.
